Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma

• DOI: 10.1039/c8bm00970h
• Publication Date: 2018-10-25T06:34:41Z
• Authors: Yang Wang; Guoqing Sui; Dengke Teng; Qimeihui Wang; Jia Qu; Lingyu Zhu; Haitao Ran; Zhigang Wang; Chunxiang Jin; Hui Wang
• Keywords: Anaplastic thyroid cancer

Currently, multifunctional nanotechnology is strongly expected to improve the prospect of treatment and diagnosis. In this study, we synthesized epidermal growth factor (EGFR)-targeted phase-changeable polymer nanoparticles (C-HPNs) loaded with two drugs (C225 10-HCPT) for specific tumor targeting, synergistic chemotherapy, ultrasound imaging under low-intensity focused (LIFU). Cetuximab (C225), an EGFR-targeted monoclonal antibody, was conjugated on surface nanoparticles, leading a significantly high binding affinity EGFR-overexpressing anaplastic thyroid C643 cells both in vitro vivo. As expected, increase more than 3- 4-fold release rates 10-HCPT observed after LIFU irradiation vitro, demonstrating that could enhance from nanoparticles. Combined C-HPNs showed excellent inhibition cell proliferation as well remarkable therapeutic effect Moreover, combined simultaneously enhanced by LIFU-induced acoustic droplet vaporization (ADV). conclusion, C225-modified exhibited great promise concurrent targeted molecular effective antitumor therapy.